ClinicalTrials.gg
RecruitingNCT06876935Guac & GrowUpdated Oct 29, 2026

Early Avocado Exposure on Development and the Gut Microbiome in American Hispanic Infants

An interventional study of Daily avocado in Gut Microbiome, Neurocognitive Correlates of Eating Habits and Infant Growth, sponsored by Arizona State University. Recruiting at 1 site in United States. Open to participants aged 3 Months to 6 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Arizona State University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Oct 29, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
3 Months to 6 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 333 studies in Feeding Behavior with a site in United States — 46 open to participants now, 66 under way, 1 of them phase 3. Feeding Behavior · United States.

Planned enrollment
70th of 271
150 · median 61
Started
2025
with 15 others
No phase
260 of 333
36 open now
Primary completion
2028-10
later than 56 of 65 live
Registered
309th of 333
by date

Among the 333 studies in Feeding Behavior with a site in United States, this one is the 70th largest by planned enrollment of the 271 interventional ones that give a count, is one of 16 that started in 2025, is one of 260 with no phase, reaches primary completion later than 56 of the 65 other live ones, and was the 309th registered.

Feeding Behavior

988 studies on the registry are indexed under Feeding Behavior; 177 are open to participants now.

Browse Feeding Behavior studies →

Open to participants now

46 of the 333 studies in Feeding Behavior with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 46 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 112 Feeding Behavior studies recruiting now, 35 (31%) set no upper age limit and 71 (63%) stop at 75 or younger; 41 take children under 18; 70 take healthy volunteers.

This study: 3 Months to 6 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 333 studies in Feeding Behavior with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if daily avocado intake can improve growth and brain and gut health in infants. The main questions it aims to answer are:

Does daily eating of avocados change which microbes live in the infant's gut? Does daily avocado intake improve infant motor skills and cognitive development?

Researchers will compare avocado intake to standard of care (no or limited avocado intake) to see if regular avocado intake from 6-12 months of life influences gut and brain health.

Participating mothers/guardians and their infants will:

Parents will provide avocado or no avocado to their infant every day for 6 months starting around 6 months of infant age.

Parents will allow study staff to visit participant homes to collect data via surveys and observations and measure infant growth.

Parents will swab soiled infant diapers for gut microbe measures. Parents will keep a diary of the infant's avocado consumption and acceptance of the food.

Parents will record their infant's dietary intake

Read the detailed description

The overarching goal of this two-arm, randomized clinical trial, is to study how early avocado exposure impacts the gut microbiome and developmental milestones in Hispanic infants. The following aims will be achieved using a randomized, parallel-arm, clinical trial.

Specific Aim 1: Evaluate how avocado consumption modulates the infant GM. Hypothesis 1: Daily avocado exposure will produce distinct structural and functional signatures within the GM compared to control.

Specific Aim 2: Investigate how avocado consumption affects emerging motor and neurocognitive skills in infants.

Hypothesis 2: Daily avocado exposure will improve development compared to the control group.

All measures will be completed at participant homes when infants are 6, 9, and 12 months of age. Infants in the intervention arm will receive a daily amount of avocado and the amount consumed will be measured. Those in the control arm will be asked to limit avocado exposure to no more than once per week.

Those in the control arm will receive the same quantity of avocados for 6 months to provide to their child once the 6-month intervention period has been completed so that control infants may also benefit from avocado consumption.

03

Conditions studied

  • Gut Microbiome
  • Neurocognitive Correlates of Eating Habits
  • Infant Growth

Browse trials for

Keywords

  • avocado
  • infants
  • complimentary feeding
  • growth
  • development
  • gut microbiome
  • neurocognitive
  • brain health
04

Who can participate

Ages eligible
3 Months to 6 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 4-6-month-old Hispanic/Latine, non-preterm (>37 weeks gestation) singleton infants
  • Infants born to mothers 18 years and older while pregnant
  • Parents speak English and/or Spanish
  • Families willing to begin feeding infants avocado around 6 months of age or when the infant is ready for solids for a total of 6 months
  • Family history of food or latex allergies will be evaluated as avocado is a latex fruit and can cause allergic responses. If either mom or dad is allergic to avocado, physician clearance for infant participation will be needed.
  • At least one caregiver in the home must have at least an 8th-grade education level

Exclusion criteria

Exclusion Criteria:

  • Infants with growth, chromosomal, or genetic abnormality, developmental and cognitive impairments, or severe comorbidity that could impact growth and development
  • Infants born with congenital abnormalities or developmental delays
  • Infant birth weights \<2500 g or >4000 g
  • Infants introduced to solid foods prior to 3 months of age
  • Biological mothers with known substance use during pregnancy (alcohol, tobacco, marijuana, or illegal drugs), or who experienced a high-risk pregnancy (e.g., preeclampsia, diabetes-Types 1 and 2 and gestational, , etc.)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Daily Avocado

    Infants in the daily avocado group will receive a daily exposure amount of avocado ranging from 1/4 (\~37.5 g or 1.25 oz) to 1/2 (\~75 g or 2.5 oz) of a medium-sized avocado.

    Other: Daily avocado

  • No intervention
    No Avocado Control

    Infants in the control group will be asked to limit avocado exposure to no more than 1/8 of a medium-sized avocado (\~19 g, 2 Tbs) once per week.

Interventions

  • OtherDaily avocado

    Infants in the daily avocado group will receive a daily exposure amount of avocado ranging from 1/4 (\~37.5 g or 1.25 oz) to 1/2 (\~75 g or 2.5 oz) of a medium-sized avocado. At 6-8 months, infants will be provided 1/4 (\~37.5 g or 1.25 oz) of a medium-sized avocado for daily consumption. Then from 9-12 months, they will begin receiving 1/2 (\~75 g or 2.5 oz) of a medium-sized avocado for daily consumption.

06

What researchers measure

Primary outcomes

  1. Gut microbiome

    Parents will collect stool samples from infant diapers using sterile swabs (parent will swab a soiled diaper) and backup soiled diapers.

    Time frame: At enrollment to the end of treatment at 6 months

Secondary outcomes

  1. Vineland Adaptive Behavior Scale (Vinland-3)

    A questionnaire completed by the parent/caregiver that is normed for ages from birth through 90 years. The tool assesses adaptive behaviors (things people do to function in everyday life) in three domains: communication, daily living skills, and socialization.

    Time frame: From enrollment to the end of treatment at 6 months

  2. McArthur Bates Communicative Development Inventories III (MBCDI-III)

    A widely used checklist completed by parents to assess children's early communication skills such as comprehension and use of gestures and words.

    Time frame: From enrollment to the end of treatment at 6 months

  3. HOME Assessment

    Research personnel will objectively evaluate the caring environment in which a child is raised and parent-child interaction using this validated assessment.

    Time frame: From enrollment to the end of treatment at 6 months

  4. Mullen Scales of Early Learning

    Study staff will administer a structured 15-minute play session with the infant to objectively assess motor, visual, and early language skills.

    Time frame: From enrollment to the end of treatment at 6 months

  5. Infant length

    Infant length will be assessed with a pediatric length board and reported in centimeters.

    Time frame: From enrollment to the end of treatment at 6 months

  6. Infant weight

    Infant weight will be assessed with a calibrated scale and reported in grams.

    Time frame: From enrollment to the end of treatment at 6 months

Other outcomes

  1. Skin Carotenoid Concentration

    The Veggie-Meter, a non-invasive measurement device, will be used to assess the carotenoid content on the index finger of the infant's right hand using reflection spectroscopy via a 2 mm wide white LED light (similar to pulse oximeter measures on the index finger).

    Time frame: From enrollment to the end of treatment at 6 months

  2. Infant 24-hour Diet Records

    Habitual intake will be assessed via the Automated Self-Administered 24-hr recall software (ASA24) on 2 weekdays and one weekend day developed by the National Cancer Institute.

    Time frame: From enrollment to the end of treatment at 6 months

  3. Food intake photos

    Pre-post meal photos of the infant and their food will be provided by the parents. These images will be used to help corroborate dietary intake and behavior data.

    Time frame: From enrollment to the end of treatment at 6 months

  4. Centers for Disease Control Infant Feeding Practices Study II Questionnaire

    This questionnaire asks about breastfeeding, formula feeding, complementary feeding, introduction to solid foods, food allergies, and participation in the Special Supplemental Nutrition Assistance Program for Women, Infant, and Children.

    Time frame: From enrollment to the end of treatment at 6 months

  5. Food Security Screener

    The USDA 6-Item Food Security Screener will be used to assess household food insecurity.

    Time frame: From enrollment to the end of treatment at 6 months

  6. Stool Consistency

    Parents will be asked to classify the stool consistency using the picture-based Brussels Infant and Toddler Stool Scale (BITSS), developed specifically for non-toilet-trained children.

    Time frame: From enrollment to the end of treatment at 6 months

07

Study locations

1 of 1 sites recruiting
  • College of Health Solutions
    Phoenix, Arizona 85004, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — To comply with the rigor and reproducibility goals of the scientific community, we will make data available when required for publication in peer-reviewed scholarly journals. Any data shared for publication will be shared in repositories such as those managed by the U.S. government (e.g. dbGAP for microbiome sequence files and associated phenotype metadata) or Arizona State University. Data will be shared with the sponsor and made available for secondary data analyses upon reasonable investigator request. Further study protocols will be made available upon request to the PI and analytical code and statistical analyses will be shared through GitHub.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: IPD and supporting information will be available no earlier than the time of first publication.

Access criteria: IPD will be accessible to investigators interested in engaging in secondary data analysis or recreating analyses done by the study team as educational exercises.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Oct 2028, 38 months after the start.

Of 503 non-industry interventional studies with no phase under Feeding Behavior, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 31. This study's planned 38 months is above that.

Counting every sponsor, half of 515 studies reached it within 14 months; a quarter within 5 and three quarters within 31.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Oct 2027 → Oct 2028 and completion Dec 2027 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2025
First posted
Mar 14, 2025
StartActual
Aug 5, 2025
Primary completionEst.
Oct 31, 2028was Oct 2027
CompletionEst.
Dec 31, 2028was Dec 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 31, 2027→Oct 31, 2028
Oct 29, 2026
Study completion
Dec 31, 2027→Dec 31, 2028
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Primary completion Oct 31, 2027→Oct 31, 2028
    Study completion Dec 31, 2027→Dec 31, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06876935
Responsible party
Corrie Whisner (Associate Professor, Arizona State University) — Principal investigator
First posted
Mar 14, 2025
Start date
Aug 5, 2025
Primary completion
Oct 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 29, 2026

Study contacts

Corrie M Whisner, PhD
Contact
cwhisner@asu.edu
602-496-3348
Rachel Tribby, BS
Contact
rtribby@asu.edu
Corrie M Whisner, PhD
principal investigator · Arizona State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion